Share on StockTwits

BioDelivery Sciences International (NASDAQ:BDSI) was downgraded by research analysts at TheStreet from a “hold” rating to a “sell” rating in a report released on Friday.

The analysts wrote, “BioDelivery Sciences International (BDSI) has been downgraded by TheStreet Ratings from hold to sell. The company’s weaknesses can be seen in multiple areas, such as its disappointing return on equity and poor profit margins.”

BioDelivery Sciences International (NASDAQ:BDSI) traded down 3.14% during mid-day trading on Friday, hitting $9.57. 681,716 shares of the company’s stock traded hands. BioDelivery Sciences International has a 52 week low of $3.86 and a 52 week high of $10.20. The stock’s 50-day moving average is $8.60 and its 200-day moving average is $7.4. The company’s market cap is $463.6 million.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its quarterly earnings results on Friday, May 9th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.04. The company had revenue of $20.69 million for the quarter, compared to the consensus estimate of $11.60 million. Analysts expect that BioDelivery Sciences International will post $-0.59 EPS for the current fiscal year.

Other equities research analysts have also recently issued reports about the stock. Analysts at Summer Street initiated coverage on shares of BioDelivery Sciences International in a research note on Thursday, May 15th. They set a “buy” rating and a $20.00 price target on the stock. Analysts at Laidlaw raised their price target on shares of BioDelivery Sciences International from $12.00 to $15.00 in a research note on Wednesday, March 5th. They now have a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating and three have issued a buy rating to the stock. BioDelivery Sciences International has an average rating of “Buy” and a consensus price target of $14.13.

BioDelivery Sciences International, Inc (NASDAQ:BDSI) is a specialty pharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.